The global acute myeloid leukemia (AML) therapeutics market is projected to expand from $3.8 billion in 2025 to $10.1 billion by 2036, registering a compound annual growth rate (CAGR) of 9.2%, according to a new report from Fact.MR, a leading market research and competitive intelligence provider. The market is expected to create an absolute dollar opportunity of approximately $5.9 billion, nearly tripling in value over the forecast period, as precision oncology and targeted therapies reshape treatment paradigms.
Targeted therapies are emerging as the leading drug class, accounting for 36% of market share in 2026, driven by increasing availability of mutation-specific drugs for genetic abnormalities such as FLT3 and NPM1. These therapies offer enhanced efficacy and improved tolerability compared to conventional chemotherapy, making them a cornerstone of modern AML treatment. The shift toward molecular diagnostics and mutation-based treatment selection is enabling clinicians to tailor therapies to individual patient profiles, reducing unnecessary toxicity and improving outcomes.
Newly diagnosed AML represents the largest patient segment, holding 48% market share in 2026, as initial treatment regimens generate high therapy volumes. Hospitals remain the dominant end user, accounting for 55% of demand, due to the intensive nature of AML care, including inpatient management, blood transfusions, and chemotherapy administration. Hospital pharmacies also lead sales channels with 49% share, reflecting the complexity and specialized handling required for AML therapies.
A significant growth driver is the expanding treatment landscape for relapsed and refractory AML. New oral targeted therapies, menin inhibitors, and mutation-specific treatments are offering options for patients who previously had limited alternatives. Recent regulatory approvals and clinical advancements continue to strengthen the pipeline, providing new hope for difficult-to-treat cases.
According to Shambhu Nath Jha, Principal Consultant at Fact.MR, "Acute myeloid leukemia therapeutics are becoming more mutation-specific and patient-risk driven. We see demand rising for oral targeted drugs and lower-intensity combinations. The future of AML treatment will increasingly depend on molecular testing, precision treatment selection, and therapies that balance efficacy with improved tolerability for diverse patient populations."
Regionally, South Asia and East Asia are emerging as high-growth markets, with India projected to grow at an 11.8% CAGR and China at 10.9%. North America continues to lead in revenue, supported by strong specialty pharmacy networks and high healthcare spending, with the United States growing at 8.7% CAGR. Western Europe remains a key market, with Germany and Japan growing at 7.9% and 7.4% CAGR, respectively.
The competitive landscape includes major pharmaceutical companies such as AbbVie Inc., Genentech (Roche), Astellas Pharma Inc., Syndax Pharmaceuticals, Inc., and Kura Oncology, Inc., which are investing heavily in precision medicine, molecular diagnostics partnerships, and clinical trials. The full report is available at Fact.MR's AML Therapeutics Report.
While challenges related to treatment costs, toxicity management, and reimbursement constraints persist, the long-term outlook remains highly positive. As mutation testing becomes integrated into routine practice, treatment decisions will become increasingly personalized and data-driven, expanding opportunities and improving patient outcomes across the global hematology landscape.
